Group 1 - The core product, Deuterated Enzalutamide soft capsule, was approved for market launch in May 2025 and included in the 2025 CSCO Prostate Cancer Diagnosis and Treatment Guidelines in June 2025. It entered the National Medical Insurance Drug List in December 2025 and was executed in January 2026 [1][3][4] - The sales strategy employs a "direct sales + agency" dual-track model, focusing on a four-wheel drive approach of "medical-market-access-sales" to build brand recognition through academic platforms and accumulate real-world data [1][3][4] - The prostate cancer market is projected to reach 50 billion yuan in China by 2030, with 146.7 million new cases globally in 2022, and 134,000 new cases in China [1][4] Group 2 - The drug HP518 is the first oral AR PROTAC in clinical stages in China, targeting metastatic castration-resistant prostate cancer (mCRPC). Phase I trials have been completed in Australia and China, with Phase II trials ongoing [2][5][6] - The company is focusing on obesity management and metabolic-associated fatty liver disease (MASH), with the weight loss market expected to grow from $282.9 billion in 2023 to $554.9 billion by 2030. The number of MASH patients in China is projected to reach 48.3 million by 2030 [2][6][7] - The core product HP515, an oral selective THR-β agonist, has shown potential in enhancing weight loss effects when combined with GLP-1, with clinical trials ongoing [2][6][8]